ArticleNeurotoxicity research2026
In vivo Administration of Atorvastatin Does Not Impair Mitochondrial Function or Cellular Viability in the Prefrontal Cortex of Mice.
Article in Neurotoxicity research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atorvastatin is a widely prescribed statin used for its cholesterol-lowering effects; however, it also exerts known pleiotropic effects, including antioxidant and anti-inflammatory properties. Atorvastatin´s impact on mitochondrial function remains controversial, with reports of toxicity in skeletal muscle and liver, while exhibiting beneficial effects on the brain. Atorvastatin has a neuroprotective effect, modulating glutamatergic transmission and reducing oxidative stress. Additionally, we previously showed that atorvastatin treatment in vivo increases mitochondrial capacity in the mouse hippocampus. Nonetheless, the bioenergetic impact of atorvastatin on the prefrontal cortex, a critical region for cognitive function, remains underexplored. This study investigated whether short-term administration of atorvastatin alters mitochondrial respiration and redox status in the prefrontal cortex of adult mice. Male Swiss mice received atorvastatin (10 mg/kg/day) or vehicle orally (p.o., in a voluntary consumption protocol) for 7 days. A behavioral analysis showed that atorvastatin slightly increased spontaneous locomotor activity and does not compromise short- (90 min) and long-term (24 h) memory in the object recognition task. The evaluation of cellular viability, cell membrane integrity, reactive oxygen species (ROS) production, and mitochondrial membrane potential in slices from the prefrontal cortex showed that atorvastatin did not induce oxidative stress, cell damage, or mitochondrial depolarization. High-resolution respirometry (HRR) was used to assess oxygen consumption rates (OCR) in prefrontal cortex homogenates, and we observed no significant alterations in any of the mitochondrial respiratory states: basal, LEAK, phosphorylating, maximal electron transfer system (ETS) capacity, or coupling efficiency. Furthermore, direct analysis of the enzymatic activity of respiratory chain complexes I and II also showed no alterations. These findings indicate that short-term atorvastatin administration is bioenergetically neutral in the murine prefrontal cortex under basal conditions, and does not compromise cognition, mitochondrial function, or cellular viability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.